Literature DB >> 10447261

A methylation PCR approach for detection of fragile X syndrome.

I Panagopoulos1, C Lassen, U Kristoffersson, P Aman.   

Abstract

Fragile X syndrome is associated with the expansion of the number of CGG trinucleotide tandem repeats at the 5' untranslated region of the FMR1 gene. The number of CGG trinucleotide repeats in normal individuals ranges between 5 and 50, in asymptomatic carrier individuals it ranges between 50 and 200, and in affected individuals it is more than 200 CGG repeats. In addition, in affected individuals the cytosine residues in the CGG repeats and the adjacent CpG island are methylated and the FMR1 gene is transcriptionally inactive. The most common diagnostic method for the detection of the syndrome is Southern blot analysis. Methods based on the polymerase chain reaction (PCR) could facilitate the rapid screening of large numbers of individuals by accurately determining the number of CGG repeats. Current PCR techniques for amplification of CGG repeats are, however, inefficient and unreliable because of their 100% C+G composition. Thus, most of the described PCR protocols require subsequent Southern blot analysis and autoradiography. We present a novel PCR approach for the diagnosis of fragile X syndrome based on the methylation-sensitive conversion of C residues to U by bisulfite on single-strand DNA and subsequent amplification of the antisense strand with specific primers. A PCR with primers for methylated C residues will amplify the CpG dinucleotide region upstream to CGG repeats exclusively in affected males. As a result of extensive mismatch between primers and bisulfite-treated DNA, no PCR fragments will be obtained in normal and transmitting males. Moreover, the bisulfite treatment dramatically reduces the C+G component of the region; thus, the high Tm and the strong secondary structures are no longer obstacles for PCR amplification. In normal and carrier individuals, UUG repeats (previously 3'-CCG-5') in the antisense strand can easily be amplified and visualized on a gel by ethidium bromide staining. We applied our method on 25 males previously diagnosed by Southern blot analysis. All the samples were easily and accurately diagnosed. The method has considerable advantages compared with other diagnostic tests for fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447261     DOI: 10.1002/(SICI)1098-1004(1999)14:1<71::AID-HUMU9>3.0.CO;2-5

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  10 in total

1.  Clinical utility gene card for: fragile X mental retardation syndrome, fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency.

Authors:  Sebastien Jacquemont; Stefanie Birnbaum; Silke Redler; Peter Steinbach; Valérie Biancalana
Journal:  Eur J Hum Genet       Date:  2011-05-04       Impact factor: 4.246

2.  A genetic study of the FMR1 gene in a Sardinian multiple sclerosis population.

Authors:  L Lorefice; S Tranquilli; G Fenu; M R Murru; J Frau; M Rolesu; G C Coghe; F Marrosu; M G Marrosu; E Cocco
Journal:  Neurol Sci       Date:  2015-07-21       Impact factor: 3.307

3.  High-resolution methylation polymerase chain reaction for fragile X analysis: evidence for novel FMR1 methylation patterns undetected in Southern blot analyses.

Authors:  Liangjing Chen; Andrew Hadd; Sachin Sah; Jeffrey F Houghton; Stela Filipovic-Sadic; Wenting Zhang; Paul J Hagerman; Flora Tassone; Gary J Latham
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822

4.  A novel methylation PCR that offers standardized determination of FMR1 methylation and CGG repeat length without southern blot analysis.

Authors:  Marina Grasso; Elles M J Boon; Stela Filipovic-Sadic; Patrick A van Bunderen; Elena Gennaro; Ru Cao; Gary J Latham; Andrew G Hadd; Domenico A Coviello
Journal:  J Mol Diagn       Date:  2013-10-29       Impact factor: 5.568

5.  Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee.

Authors:  A Maddalena; C S Richards; M J McGinniss; A Brothman; R J Desnick; R E Grier; B Hirsch; P Jacky; G A McDowell; B Popovich; M Watson; D J Wolff
Journal:  Genet Med       Date:  2001 May-Jun       Impact factor: 8.822

6.  Molecular diagnosis of Fragile X syndrome in subjects with intellectual disability of unknown origin: implications of its prevalence in regional Pakistan.

Authors:  Madiha Kanwal; Saadia Alyas; Muhammad Afzal; Atika Mansoor; Rashda Abbasi; Flora Tassone; Sajid Malik; Kehkashan Mazhar
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240

7.  Methyl-CpG-binding PCR of bloodspots for confirmation of fragile X syndrome in males.

Authors:  Ching-Cherng Tzeng; Chiou-Ping Liou; Chien-Feng Li; Ming-Chi Lai; Li-Ping Tsai; Wei-Chen Cho; Hui-Ting Chang
Journal:  J Biomed Biotechnol       Date:  2009-11-04

8.  Laboratory testing for fragile X, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Elaine Spector; Andrea Behlmann; Kathryn Kronquist; Nancy C Rose; Elaine Lyon; Honey V Reddi
Journal:  Genet Med       Date:  2021-04-01       Impact factor: 8.822

Review 9.  Fragile X syndrome in Korea: a case series and a review of the literature.

Authors:  Shin-Young Yim; Bo Hyun Jeon; Jung A Yang; Hyon J Kim
Journal:  J Korean Med Sci       Date:  2008-06       Impact factor: 2.153

Review 10.  Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related Disorders.

Authors:  Indhu-Shree Rajan-Babu; Samuel S Chong
Journal:  Genes (Basel)       Date:  2016-10-14       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.